Engineered nanoparticles for endocrine tumor targeting, current progress and future outlook.

Area of Science:

• Endocrinology
• Oncology
• Nanotechnology
• Theranostics

Background:

• Endocrine tumors present diagnostic and therapeutic challenges due to complexity, delayed detection, and poor response to conventional treatments.
• Tumor heterogeneity, drug resistance, and systemic toxicity limit current therapeutic success.
• Nanotechnology offers a novel theranostic approach to enhance drug bioavailability and precision delivery.

Purpose of the Study:

• To review the application of nanoparticle-based therapies for endocrine cancers.
• To discuss mechanisms of action, targeted delivery strategies, and theranostic applications of nanoparticles.
• To explore limitations of current therapies and future prospects of nanoparticle-based treatments for endocrine malignancies.

Main Methods:

• Review of engineered nanoparticles (lipid-based, polymeric, inorganic) for targeted endocrine cancer therapy.
• Discussion of active targeting (ligand-receptor) and passive accumulation (EPR effect) strategies.
• Analysis of nanoparticle mechanisms, including drug resistance mitigation and adaptation to tumor microenvironment.

Main Results:

• Nanoparticles enhance drug delivery precision, improving bioavailability and reducing systemic toxicity.
• Targeted nanoparticle delivery addresses drug resistance and rapid clearance issues.
• Responsive and biomimetic nanoparticles adapt to dynamic tumor microenvironments.

Conclusions:

• Nanoparticle-based theranostics represent a promising advancement in endocrine cancer treatment.
• Targeted drug delivery via nanoparticles overcomes key limitations of conventional therapies.
• Further research into nanoparticle-based therapies holds significant potential for improving patient outcomes in endocrine oncology.